Sound Income Strategies LLC Raises Holdings in DENTSPLY SIRONA Inc. $XRAY

Sound Income Strategies LLC increased its position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 32.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 611,308 shares of the medical instruments supplier’s stock after buying an additional 149,384 shares during the quarter. Sound Income Strategies LLC owned about 0.31% of DENTSPLY SIRONA worth $7,464,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in DENTSPLY SIRONA in the 1st quarter valued at $26,000. Huntington National Bank increased its holdings in DENTSPLY SIRONA by 292.9% in the 3rd quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 2,077 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in DENTSPLY SIRONA by 337.9% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 2,122 shares in the last quarter. True Wealth Design LLC increased its holdings in DENTSPLY SIRONA by 49.7% in the 3rd quarter. True Wealth Design LLC now owns 3,557 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 1,181 shares in the last quarter. Finally, Central Pacific Bank Trust Division increased its holdings in DENTSPLY SIRONA by 100.0% in the 3rd quarter. Central Pacific Bank Trust Division now owns 4,000 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 2,000 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors and hedge funds.

DENTSPLY SIRONA Stock Up 0.1%

NASDAQ:XRAY opened at $11.64 on Tuesday. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of -3.88, a price-to-earnings-growth ratio of 1.37 and a beta of 0.99. DENTSPLY SIRONA Inc. has a one year low of $9.85 and a one year high of $17.18. The stock has a 50-day simple moving average of $12.45 and a 200 day simple moving average of $12.11. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The firm had revenue of $961.00 million during the quarter, compared to analyst estimates of $926.40 million. DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the business posted $0.26 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts predict that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

Insider Transactions at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Gregory T. Lucier bought 27,555 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were purchased at an average price of $14.24 per share, with a total value of $392,383.20. Following the completion of the acquisition, the director directly owned 27,555 shares of the company’s stock, valued at approximately $392,383.20. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director James D. Forbes bought 5,000 shares of the business’s stock in a transaction on Monday, March 9th. The stock was acquired at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the acquisition, the director directly owned 10,000 shares of the company’s stock, valued at $124,800. The trade was a 100.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 70,000 shares of company stock valued at $956,437 over the last quarter. Insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

XRAY has been the subject of several recent research reports. Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and increased their price target for the company from $13.00 to $17.00 in a report on Thursday, February 19th. Robert W. Baird increased their price target on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, February 27th. Barrington Research increased their price target on DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a report on Monday, March 2nd. Zacks Research upgraded DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Finally, Barclays initiated coverage on DENTSPLY SIRONA in a report on Monday, December 8th. They issued an “underweight” rating and a $12.00 price target for the company. Three analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $14.42.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.